AU2017233923B2 - Treatment of severe Community Acquired Pneumonia - Google Patents

Treatment of severe Community Acquired Pneumonia Download PDF

Info

Publication number
AU2017233923B2
AU2017233923B2 AU2017233923A AU2017233923A AU2017233923B2 AU 2017233923 B2 AU2017233923 B2 AU 2017233923B2 AU 2017233923 A AU2017233923 A AU 2017233923A AU 2017233923 A AU2017233923 A AU 2017233923A AU 2017233923 B2 AU2017233923 B2 AU 2017233923B2
Authority
AU
Australia
Prior art keywords
igm
equal
level
serum
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017233923A
Other languages
English (en)
Other versions
AU2017233923A1 (en
Inventor
Benjamin Daelken
Patrick Langohr
Ulrike Wippermann
Andrea Wartenberg-Demand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest AG
Original Assignee
Biotest AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest AG filed Critical Biotest AG
Publication of AU2017233923A1 publication Critical patent/AU2017233923A1/en
Application granted granted Critical
Publication of AU2017233923B2 publication Critical patent/AU2017233923B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017233923A 2016-03-14 2017-03-13 Treatment of severe Community Acquired Pneumonia Active AU2017233923B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16160175.2 2016-03-14
EP16160175 2016-03-14
EP16185173 2016-08-22
EP16185173.8 2016-08-22
PCT/EP2017/055838 WO2017157850A1 (en) 2016-03-14 2017-03-13 Treatment of severe community acquired pneumonia

Publications (2)

Publication Number Publication Date
AU2017233923A1 AU2017233923A1 (en) 2018-08-09
AU2017233923B2 true AU2017233923B2 (en) 2023-10-12

Family

ID=58413057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017233923A Active AU2017233923B2 (en) 2016-03-14 2017-03-13 Treatment of severe Community Acquired Pneumonia

Country Status (10)

Country Link
US (4) US20190076523A1 (enExample)
EP (2) EP3851123A1 (enExample)
JP (1) JP7041634B2 (enExample)
CN (1) CN108778333A (enExample)
AU (1) AU2017233923B2 (enExample)
CA (1) CA3013849A1 (enExample)
ES (1) ES2881201T3 (enExample)
PL (1) PL3429622T3 (enExample)
RU (1) RU2735680C2 (enExample)
WO (1) WO2017157850A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747903A1 (en) 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
CA3195385A1 (en) 2020-11-19 2022-05-27 Biotest Ag Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19
CN112485448B (zh) * 2020-11-20 2021-08-24 浙江大学 Nmi蛋白作为生物靶标在制备成人社区获得性肺炎严重程度及预后评估试剂盒的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001319A1 (en) 1977-08-18 1979-04-04 Beecham Group Plc Process for the preparation of hydroxyphenyl hydantoin and of hydroxyphenyl glycine, and compounds thus obtained
DE2901822A1 (de) 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
JP2010512350A (ja) * 2006-12-11 2010-04-22 ダラグレキュル・アンパルトセルスカブ ホスホマイシンの肺投与により細菌感染を伴う嚢胞性線維症または肺炎を処置するための方法
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
US20130196310A1 (en) * 2008-05-20 2013-08-01 Rapid Pathogen Screening, Inc. Method and Device for Combined Detection of Viral and Bacterial Infections
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
GB201006753D0 (en) * 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
RU2470664C2 (ru) * 2010-08-23 2012-12-27 Андрей Германович Лютов Способ получения иммуноглобулина для внутривенного введения, обогащенного иммуноглобулином м, и препарат, полученный этим способом
CN104254542A (zh) 2012-03-09 2014-12-31 瑞士杰特贝林生物制品有限公司 包含分泌-样免疫球蛋白的组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: *
WELTE TOBIAS ET AL: RESPIRATORY MEDICINE, vol. 109, no. 6, 2 April 2015 (2015-04-02), pages 758 - 767 *

Also Published As

Publication number Publication date
JP7041634B2 (ja) 2022-03-24
CA3013849A1 (en) 2017-09-21
CN108778333A (zh) 2018-11-09
EP3429622B1 (en) 2021-04-21
US11517621B2 (en) 2022-12-06
JP2019508458A (ja) 2019-03-28
US20230241210A1 (en) 2023-08-03
US12186391B2 (en) 2025-01-07
WO2017157850A1 (en) 2017-09-21
RU2735680C2 (ru) 2020-11-05
EP3429622A1 (en) 2019-01-23
RU2018135290A (ru) 2020-04-15
RU2018135290A3 (enExample) 2020-04-16
US20210162043A1 (en) 2021-06-03
US20200268881A1 (en) 2020-08-27
AU2017233923A1 (en) 2018-08-09
US10918715B2 (en) 2021-02-16
US20190076523A1 (en) 2019-03-14
ES2881201T3 (es) 2021-11-29
EP3851123A1 (en) 2021-07-21
PL3429622T3 (pl) 2021-11-02

Similar Documents

Publication Publication Date Title
US12186391B2 (en) Treatment of severe community acquired pneumonia
JP6441888B2 (ja) 自己免疫性障害の処置におけるレボセチリジン及びモンテルカストの使用
Lin et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency
Roord et al. Inherited deficiency of the third component of complement associated with recurrent pyogenic infections, circulating immune complexes, and vasculitis in a Dutch family
Weisman et al. Intravenous immune globulin prophylaxis of late-onset sepsis in premature neonates
JPS5920229A (ja) 強化されたオプソニン活性を有する組成物
CN113905760A (zh) 用于治疗化脓性汗腺炎的抗IL-α抗体
EP3383884A1 (en) Method for preventing or treating nosocomial pneumonia
Ito et al. Pharmacokinetics of glycopeptide antibiotics in children
Hagihara et al. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus
CA3174566A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
Kim et al. A case of acute cerebral aspergillosis complicating influenza A/H1N1pdm 2009
US10975131B2 (en) Factor H-Fc immunotheraphy
HK40046908A (en) Treatment of severe community acquired pneumonia
RU2736481C2 (ru) Композиции и способы для лечения вируса гриппа
Nouailles et al. Trimodulin supports antibacterial defence and restricts inflammation in preclinical pneumonia models
US8691752B2 (en) Protein product for treatment of infectious diseases and related inflammatory processes
HK1259313A1 (en) Treatment of severe community acquired pneumonia
HK1259313B (en) Treatment of severe community acquired pneumonia
Blin et al. The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
Gharebaghi et al. Intravenous Immunoglobulin Gamma for Severe Cases of Coronavirus Disease of 2019: A Randomized Placebo-Controlled Double-Blinded Clinical Trial
US20080070846A1 (en) Treating acute exacerbations of asthma using a ketolide
El-Belazi Intravenous immunoglobulin prophylaxis of late-onset sepsis in preterm neonates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)